[{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Institute of Cancer Research, United Kingdom | Onyx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ONX-0801","moa":"antineoplastic thymidylate synthetase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Institute of Cancer Research, United Kingdom | Onyx Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Institute of Cancer Research, United Kingdom | Onyx Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals for ONX 0801
Details :
ONX-0801 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Reset All
